诱导多功能干细胞治疗缺血性卒中:诱惑与现实  

Inducible Pluripotent Stem Cells for the Treatment of Ischemic Stroke: Entice and Current Status

作　　者：刘宇恒[1] 许治强[1] 梁燕玲[1] 李斯颖[1] 林永强[1] 

机构地区：[1]广州医科大学附属第三医院神经内科,广州510150

出　　处：《中国卒中杂志》2015年第10期902-905,共4页Chinese Journal of Stroke

基　　金：广州医科大学青年科研项目(2013A14)

摘　　要：诱导多能干细胞(induced pluripotent stem cells,i PSC)由特定的转录因子转录已分化的体细胞而来,在生物学功能方面与胚胎干细胞(embryonic stem cell,ESC)类似。实际应用中,i PSC在细胞来源、免疫原性和医学伦理等方面面临较少的困境,从而为疾病提供更多的临床治疗策略。在治疗方面与普通干细胞相比,具有更多的优越性,但i PSC的致瘤性、诱导率低等问题,仍有待进一步解决。本文将重点探讨i PSC治疗缺血性卒中的研究现状、发展制约及未来展望。Induced pluripotent stem cells induced pluripotent stem cells （iPSC） are a class of cells by introducing the specific transcription factors into adult cells, and similar to embryonic stem cells in biological function. And iPSC in the use of the cell source, immunogenicity and medical ethics, and so on to face less dififcult, so as to provide more clinical treatment strategies for the disease. Compared with the common stem cells in treatment, it has more advantages, but the iPSC of the tumor and the induction rate is low. This article will focus on the research status, development and future prospect of iPSC in treating ischemic stroke.

关 键 词：缺血性卒中 诱导多能干细胞 治疗 

分 类 号：R743.3[医药卫生—神经病学与精神病学]